No Detail Found!

Electrocardiographic and biochemical adverse effects of meglumine antimoniate (MA) during treatment of Syrian cutaneous leishmaniasis patients.

Author(s)
Siavash M Shanehsaz Department of Dermatology and Venereology, Aleppo University Hospital, Syria
Silva Ishkhanian Department of Dermatology and Venereology, Aleppo University Hospital, Syria
Abstract
Objective: To evaluate the effect of meglumine antimoniate (MA) on EKG and some liver, kidney, and pancreas function tests among Syrian cutaneous leishmaniasis (CL) patients. Patients and methods: In this prospective study, of 80 Syrian clinically suspected CL patients referred to the Aleppo University Hospital Clinic, 50 patients were randomly selected and after the diagnosis of CL was made by tissue smear and skin biopsy, EKG and blood samples were taken to evaluate liver, kidney, and pancreas function tests before and after treatment with intramuscular injections of MA at a dose of 20 mg Sb5+/kg/day equivalent to 60 mg/kg/day for 21 days. Informed consent was obtained from all the cases. Data were analyzed by use of paired t test and p values 5+/kg/day equivalent to 60 mg/kg/day (MA) for 21 days does not significantly alter the liver, kidney and pancreas function tests. Treatment with systemic (MA) can induce many ECG changes as QT prolongation, a significant risk. Identification of factors before and during treatment that may increase the risk of QTc prolongation and arrhythmias is important. Systemic (MA) can be used safely in this population with adequate monitoring and the need for treatment interruption is uncommon.
Publication Details
Page(s) 412-417
DOI DOI not available
Published Journal: Journal of Pakistan Association of Dermatologists, Volume: 23, Issue: 4, Year: 2013

Request the full text from PASTIC

0

Citations

0

Downloads

45

Views